Nervous System News and Research

Latest Nervous System News and Research

Plymouth researchers receive grant to develop effective therapy for Huntington's disease

Huntington's disease is an hereditary disorder of the nervous system caused by a faulty gene on chromosome four. The faulty gene leads to nerve damage in the area of the brain resulting in gradual physical, mental and emotional changes. Those born to a parent with Huntington's disease have a 50:50 chance of developing it, and there is currently no cure.

9 Apr 2015

TSRI scientists find molecular trigger of schizophrenia-like behaviors and brain changes

According to the World Health Organization, more than 21 million people worldwide suffer from schizophrenia, a severe psychiatric disorder that can cause delusions and hallucinations and lead to increased risk of suicide...

8 Apr 2015

Scientists identify brain molecule that triggers schizophrenia-like behaviors, brain changes

Scientists at The Scripps Research Institute have identified a molecule in the brain that triggers schizophrenia-like behaviors, brain changes and global gene expression in an animal model. The research gives scientists new tools for someday preventing or treating psychiatric disorders such as schizophrenia, bipolar disorder and autism.

8 Apr 2015

National MS Society commits $28 million to support new MS research projects, training awards

The National Multiple Sclerosis Society has committed $28 million to support an expected 84 new MS research projects and training awards. These are part of a comprehensive research strategy aimed at stopping MS, restoring function that has been lost, and ending the disease forever – for every single person with MS.

8 Apr 2015

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Rhythm, a biopharmaceutical company, and Actavis plc, a leading global pharmaceutical company, announced today the initiation of a Phase 2b clinical trial assessing the efficacy and safety of relamorelin (RM-131), Rhythm's ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes.

8 Apr 2015

Researchers explore influence of low-frequency magnetic fields on neurodegenerative disorders

Low-frequency alternating magnetic fields such as those generated by overhead power lines are considered a potential health risk because epidemiological studies indicate that they may aggravate, among other things, neurodegenerative disorders such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

8 Apr 2015

Combining nortriptyline and morphine successfully relieves chronic neuropathic pain

The combination of two well-known drugs will have unprecedented effects on pain management, says new research from Queen's.

8 Apr 2015

Study identifies genetic variants linked to Hirschsprung’s disease

Genetic studies in humans, zebrafish and mice have revealed how two different types of genetic variations team up to cause a rare condition called Hirschsprung’s disease. The findings add to an increasingly clear picture of how flaws in early nerve development lead to poor colon function, which must often be surgically corrected.

8 Apr 2015

Study reveals how cell's protein quality control mechanism helps combat neurodegenerative diseases

A molecular pathway known to suppress tumors appears to also be a major player in clearing cells of damaged proteins implicated in neurodegenerative diseases such as ALS and certain types of dementia, new research in roundworms and human cells suggests.

6 Apr 2015

Actavis seeks FDA marketing approval for Ambrisentan Tablets, 5 mg and 10 mg

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg.

6 Apr 2015

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed, Inc. today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched.

6 Apr 2015

Peripheral inflammatory cells play role in Parkinson's disease

A small area in the midbrain known as the substantia nigra is the control center for all bodily movement. Increasing loss of dopamine-generating neurons in this part of the brain therefore leads to the main symptoms of Parkinson's disease - slowness of movement, rigidity and shaking.

3 Apr 2015

Nanoparticle technique inhibits tumor growth, prolongs survival in animal models

Delving into the world of the extremely small, researchers are exploring how biodegradable nanoparticles can precisely deliver anticancer drugs to attack neuroblastoma, an often-deadly children's cancer.

3 Apr 2015

Study calls for more intensive psychotherapeutic support for patients with alcohol addiction

The mortality of alcohol dependent patients in general hospitals is many times higher than that of patients without alcohol dependency.

3 Apr 2015

Omeros announces commercial availability of Omidria in U.S.

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, announced today the nationwide commercial availability of Omidria (phenylephrine and ketorolac injection) 1%/0.3%.

2 Apr 2015

Idiopathic central precocious puberty on the rise in boys

About three-quarters of cases of central precocious puberty in boys have no identifiable cause, say researchers.

1 Apr 2015

Research breakthrough could help develop tools to repair damaged nerve cells

A team of researchers at the IRCM led by Frédéric Charron, PhD, in collaboration with bioengineers at McGill University, uncovered a new kind of synergy in the development of the nervous system, which explains an important mechanism required for neural circuits to form properly.

1 Apr 2015

Understanding how neurons work

Before scientists can unlock the secrets of the human brain, they must fully understand neurons—the cells of our brain, spinal cord and overall nervous system. Thousands of detailed neuron images, from different organisms, currently sit in individual data collections across the globe, comprising several petabytes of data altogether.

1 Apr 2015

Neurocrine Biosciences, Mitsubishi Tanabe to develop and commercialize NBI-98854 in select Asian markets

Neurocrine Biosciences, Inc. today announced that it has entered into an exclusive collaboration and licensing agreement for the development and commercialization of its VMAT2 inhibitor, NBI-98854, in Japan and other select Asian markets with Mitsubishi Tanabe Pharma Corporation.

1 Apr 2015

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

Nektar Therapeutics reported that partner AstraZeneca announced today that MOVANTIK (naloxegol) has launched in the United States. On September 16, 2014, the US Food and Drug Administration (FDA) approved MOVANTIK as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain.

31 Mar 2015

Nervous System News and Research

Latest Nervous System News and Research

Plymouth researchers receive grant to develop effective therapy for Huntington's disease

TSRI scientists find molecular trigger of schizophrenia-like behaviors and brain changes

Scientists identify brain molecule that triggers schizophrenia-like behaviors, brain changes

National MS Society commits $28 million to support new MS research projects, training awards

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Researchers explore influence of low-frequency magnetic fields on neurodegenerative disorders

Combining nortriptyline and morphine successfully relieves chronic neuropathic pain

Study identifies genetic variants linked to Hirschsprung’s disease

Study reveals how cell's protein quality control mechanism helps combat neurodegenerative diseases

Actavis seeks FDA marketing approval for Ambrisentan Tablets, 5 mg and 10 mg

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Peripheral inflammatory cells play role in Parkinson's disease

Nanoparticle technique inhibits tumor growth, prolongs survival in animal models

Study calls for more intensive psychotherapeutic support for patients with alcohol addiction

Omeros announces commercial availability of Omidria in U.S.

Idiopathic central precocious puberty on the rise in boys

Research breakthrough could help develop tools to repair damaged nerve cells

Understanding how neurons work

Neurocrine Biosciences, Mitsubishi Tanabe to develop and commercialize NBI-98854 in select Asian markets

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Nervous System News and Research

Latest Nervous System News and Research

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Newsletters you may be interested in